Evidence map›Paper›PMID 31300280›Full record

Trial reportThe Journal of allergy and clinical immunology2019

Randomized controlled trial demonstrating the benefits of delta inulin adjuvanted immunotherapy in patients with bee venom allergy.

Robert Heddle, Anthony Smith, Richard Woodman, Pravin Hissaria, Nikolai Petrovsky

Abstract readClinical Trial, Phase IClinical Trial, Phase IIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The Journal of allergy and clinical immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. A Pilot Randomised Controlled Dose-Ranging Trial of Ant Venom Immunotherapy With and Without Delta-Inulin Adjuvant.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2026
    Trial
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Robert HeddleUniversity of Adelaide, North Terrace, Adelaide, Australia; Royal Adelaide Hospital, North Terrace, Adelaide, Australia; Flinders University, Bedford Park, Australia.
Anthony SmithAllergy and Clinical Immunology Department, Flinders Medical Centre, Bedford Park, Australia.
Richard WoodmanFlinders Centre for Epidemiology and Biostatistics, Flinders University, Bedford Park, Australia.
Pravin HissariaRoyal Adelaide Hospital, North Terrace, Adelaide, Australia.
Nikolai PetrovskyFlinders University, Bedford Park, Australia; Vaxine, Bedford Park, Australia. Electronic address: nikolai.petrovsky@flinders.edu.au.

Funding

Novel vaccine adjuvants to counter bioterrorist threatsU01AI061142 · NIAID · FLINDERS UNIVERSITY OF SOUTH AUSTRALIA · PI PETROVSKY, NIKOLAI · 2005 to 2009
$3.5M
NIAID NIH HHS HHSN272200800039CNIAID NIH HHS HHSN272201400053CNIAID NIH HHS U01 AI061142
6 · The paper itself

Abstract

backgroundAllergic reactions to Hymenoptera insect stings remain a major global clinical problem. Although effective, parenteral desensitization regimens require use of costly venom extracts and require frequent visits over extended periods of time.

objectiveAdjuvants are commonly used to enhance the efficacy of infectious disease vaccines, and this study asked whether Advax (Vaxine Pty Ltd, Adelaide, Australia), a novel noninflammatory polysaccharide adjuvant, might provide similar benefits for allergy desensitization.

methodsA randomized, controlled phase 1/2 trial was undertaken in 27 adults with a history of rapid-onset systemic allergic reactions to honeybee stings and positive specific IgE levels to evaluate the safety and efficacy of honeybee venom immunotherapy (HBVIT) combined with Advax adjuvant. Venom immunotherapy (VIT) was administered monthly for 30 months after achievement of maintenance doses.

resultsAdvax-adjuvanted HBVIT was well tolerated. Around week 14 of VIT, specific IgG

conclusionAdvax adjuvant favorably enhanced the immunogenicity of HBVIT, with an early and prolonged switch to specific IgG

Indexed as

HypersensitivityImmunotherapyInsect Bites and StingsAdjuvants, ImmunologicAdultAgedBee VenomsFemaleHumansImmunoglobulin EInulinMaleMiddle AgedAdjuvants, ImmunologicBee Venomsdelta inulinImmunoglobulin EInulinadjuvantallergyanaphylaxisHymenopteraIgG(4)immunotherapyinulin

Identifiers

PMID31300280
PMCPMC7112352

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.